A Chinese surgeon remotely operated a robotic system to remove a prostate tumor from a patient 220 kilometers away. Utilizing ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Original Medicare (parts A and B) covers medically necessary prostate surgeries, including treatments for an enlarged prostate and prostate cancer. Medicare covers various prostate procedures, ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

New research suggests that men who undergo surgery to remove their prostate as a result of prostate cancer report a decrease in penis size. The knowledge that prostatectomy can decrease penis size is ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...